Related Concept Videos
Position-effect Variegation
Personal Identity
Position and Displacement
Serial Position Effect
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Self-Report Tests of Personality
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Potential Economic Value of Multi-cancer Early Detection Testing Under Differential Cost Trends for Cancer Screening and Management.
Regulatory Aspects of Artificial Intelligence and Machine Learning.
Related Experiment Video
Updated: Feb 10, 2026

Using Micro-Electro-Mechanical Systems MEMS to Develop Diagnostic Tools
Published on: October 1, 2007
Personalized diagnostics: the struggle for position.
1Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210, USA. bquinn@foleyhoag.com.
Advances in molecular diagnostics promise personalized medicine but face financial hurdles. Innovative tests require new payment models to overcome the gap between falling lab costs and high clinical trial expenses.
Area of Science:
- Biotechnology
- Health Economics
- Medical Diagnostics
Background:
- Biomarker-guided drug selection is established in major cancers like breast and lung cancer.
- Rapid advancements in genomic and proteomic technologies could expand molecular testing across all medical fields.
- Current healthcare economic models may impede the adoption of innovative molecular diagnostics.
Purpose of the Study:
- To identify significant barriers to the widespread adoption of molecular diagnostics.
- To propose solutions for the financial and regulatory challenges facing molecular diagnostic innovation.
Main Methods:
- Analysis of the economic landscape for laboratory testing.
- Examination of current healthcare payer coverage frameworks for medical interventions.
Main Results:
- A widening gap exists between declining molecular test costs and the substantial investment needed for clinical trials and regulatory approval.
- Existing payer coverage frameworks, focused on improved health outcomes, may not adequately accommodate the unique evaluation needs of molecular diagnostics.
Conclusions:
- Without financial and regulatory adjustments, promising molecular diagnostic innovations may not be developed or implemented.
- New evaluation and reimbursement strategies are essential to support the integration of molecular diagnostics into routine clinical practice.

